Neurology Clinical Trials Market: Segmented: By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Indication (Epilepsy, Parkinson's Disease [PD], Huntington's Disease, Stroke, Traumatic Brain Injury [TBI], Amyotrophic Lateral Sclerosis [ALS], Muscle Regeneration, Others), And Region - Global Analysis Of Market Size, Share & Trends For 2021-2022 And Forecasts To 2032
Neurology Clinical Trials Market to surpass USD 11.4 Billion by 2032 from USD 5.83 Billion in 2021 at a CAGR of 6.3% in the coming years, i.e., 2022-32.
Clinical trials are research projects that comprise volunteer members. The study of neurology is essential to patient care. These investigations by medical scientists on humans help in the improved understanding, diagnosis, treatment, and prevention of illnesses and ailments. The outcomes and results of researchers help neurologists better diagnose and treat patients with brain and nervous system problems. The physician-scientists contribute to improvements in the neurological care of patients worldwide. Clinical trials in neurology cover a variety of topics, like Alzheimer's disease, multiple sclerosis, epilepsy, Parkinson's disease, and new treatments for neurological illnesses with familial tendencies. Such organizations coordinate national clinical trials with other medical institutions and have thousands of other ongoing clinical trials and research investigations.
The factors that are largely responsible for the growth of the neurology clinical trials market are strict regulatory standards governing clinical trials and the National Institute of Neurological Disorders and Stroke (NINDS), which receives more government funding than other organizations for conducting clinical trials. Another factor contributing to the market growth is the gradual rise in the number of licensing agreements relating to neuroscience over the past ten years.
Neurology Clinical Trials market is categorized on the basis of Phase into Phase I, Phase II, Phase III, and Phase IV. In terms of market share, the phase II clinical trials segment led the neurology clinical trials market in 2020. This is mainly due to neurological conditions that are highly uncommon and do not have specific treatments.
Phase III is predicted to exhibit the strongest increase during the forecast period. Phase III clinical studies, which are the most expensive and involve the most participants, are the reason for the segment growth. Phase III requires more patients and, frequently is a longer treatment.
Neurology Clinical Trials market is categorized on the basis of Study Design into Interventional, Observational, and Expanded Access. Over the forecast period, it is anticipated that the observational segment would capture significant growth. Observational studies are frequently used to assess treatment outcomes in a number of circumstances, such as post-marketing safety assessments of medications or when clinical trials are not practical. In observational studies, there are frequent differences between treatment groups in the prevalence of important prognostic markers associated with both therapy and outcome.
The Industry Witnessing a Healthy Level of Early Investment
Neuroscience is still witnessing a high level of early funding. Early detection of diseases is drawing investment and fostering deal-making in the complex neuroscience sector, particularly for pain and Alzheimer's disease, as the industry works to move on over the numerous late-stage clinical failures in the past years. Neuroscience is one of the closest competitors, but no other therapeutic field matches oncology in terms of deal volume. The vast majority of agreements in the field of neuroscience are primarily neurological in nature, which is consistent with the degree of R&D activity in the two fields. These factors are anticipated to boost market growth.
The Rising Number of Neurological Diseases and Availability of Improved Tools for Better Analysis
Increases in neurological conditions like stroke, dementia, and peripheral neuropathy, as well as rising R&D expenditures on neurological research, are mostly to blame for the growth of the neurology clinical trials market. Drug companies currently have more advanced techniques for modifying and fixing genes than they did in the early 20th century. Due to this, diseases brought on by solitary genetic mutations, such as spinal muscular atrophy, seem to be simpler to treat and less dangerous, qualities that would appeal to huge firms thinking on returning in neuroscience. This is a motivating aspect that is causing the market to expand.
Increasing Failure Rates of the Neurology Clinical Trials
Through drug discovery activities, thousands of molecules are tested during the drug development pipeline, with hundreds moving on to the preclinical stage. About 1 chemical out of every 10 that make it to human research is commercially available. This entire procedure often takes between 10 to 15 years. Every stage of development has seen a rise in clinical trial failures, which has a negative effect on productivity in research and development (R&D). The market growth is being hampered by this factor.
Neurology Clinical Trials market is segmented based on regional analysis into five major regions: North America, Latin America, Europe, Asia Pacific and the Middle East and Africa. In terms of revenue share, North America dominated the market for neurology clinical trials in 2020. The market for neurology clinical trials in the region is driven by the increased frequency of neurological disorders and the existence of numerous companies in clinical trials.
The Covid-19 pandemic is an extraordinary occurrence that has affected virtually every aspect of corporate operations worldwide. The pharmaceutical industry is being enlisted to help develop an efficient therapy against the pandemic as soon as possible. Clinical trials that are now underway have been delayed due to problems with study enrollment, data collection, and data analysis.
|Market size value in 2021||USD 5.83 Billion|
|Revenue forecast in 2032||USD 11.4 Billion|
|Growth Rate||CAGR of 6.3% from 2022 to 2032|
|Base year for estimation||2021|
|Quantitative units||Revenue in USD million and CAGR from 2022 to 2032|
|Report coverage||Revenue forecast, company ranking, competitive landscape, growth factors, and trends|
|Segments covered||Phase, Study Design, Indication, and Region|
|Regional scope||North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)|
|Key companies profiled||Abbott Laboratories, Novartis, Labcorp Drug Development, Charles River Laboratories, GlaxoSmithKline, Pfizer, Aurora healthcare, Medpace, Syneous Health, Icon Plc, Biogen, Amgen, Merck, AstraZeneca, Bristol Myers Squibb, and Other Prominent Players.|
The Neurology Clinical Trials market size was estimated at USD 5.83 Billion in 2021 and is expected to reach USD 11.4 Billion in 2032.
Clinical Trials in Neurology comprise the methodology and layout of clinical trials for neurological diseases in great detail.
The Phase III and Observational segments accounted for the larger share of the Neurology Clinical Trials Market.
Key players in the Neurology Clinical Trials market are Abbott Laboratories, Novartis, Labcorp Drug Development, Charles River Laboratories, GlaxoSmithKline, Pfizer, Aurora healthcare, Medpace, Syneous Health, Icon Plc, Biogen, Amgen, Merck, AstraZeneca, Bristol Myers Squibb, and Other Prominent Players.
The increase in neurological illnesses like stroke, dementia, and peripheral neuropathy as well as increased R&D activities are the primary drivers of the neurology clinical trials market.
Select License Type
US : +1 (716) 218-3733
UK : +44 (208) 1235555
Select License Type
FATPOS CLIENT Appriciation DURING THE PROJECT